Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Scholl and College of Podiatry partner ahead of Foot Health Month

Scholl has partnered with the College of Podiatry to inform pharmacists and patients about footcare during the college’s Foot Health Month in April.

The partnership – announced last month – aims to raise awareness of the importance of good foot health, manufacturer Reckitt Benckiser (RB) said.

The College of Podiatry is a London-based professional body for the UK’s registered podiatrists. It has chosen April for its annual Foot Health Month campaign, to help educate healthcare professionals and the public on how to care for their feet, RB said.

Together with Scholl, the college will develop a package of footcare-tailored assets, including a training tool and in-depth CPD module, which will be available “from spring”, the manufacturer added.

For more information, visit the Scholl or College of Podiatry websites

Would you like more footcare knowledge?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD005750

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel